**THE UNIVERSITY OF MICHIGAN**
**REGENTS COMMUNICATION**

**ACTION REQUEST**

**Subject:** Sponsored Activity Agreement between the University of Michigan and MeiraGTx Limited

**Action Requested:** Authorization to enter into Agreement

**Preamble:**

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed sponsored activity agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor Robin Ali is an employee of the University of Michigan ("University"), and a partial owner of MeiraGTx Limited. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

**Background:**

Robin Ali, PhD, FMedScia, a Visiting Professor in the Department of Ophthalmology and Visual Science, is the Chief Scientific Officer and partial owner of MeiraGTx Limited (the “Company”). The Company wishes to fund a sponsored activity entitled, “Meira CSA for Clinical Trial Support” (ORSP #19-PAF06723) in the Department of Ophthalmology and Visual Science under the direction of Dr. Grant Comer. The purpose of this agreement is to hire and train a research assistant to facilitate clinical research, perform clinical assessments, and provide support for increased enrollment and the required data collection and testing. This work is supplemental to individual contracts and applies to all MeiraGTx sponsored clinical trials.

**Agreement Terms:**

The terms of the Agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $998,975. Since projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
Impact of the Agreement:

The Agreement will support an effort by Dr. Comer to provide personnel and research subject travel support for ongoing and future MeiraGTx Limited-sponsored clinical research conducted by the University pursuant to the Agreements.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with MeiraGTx Limited.

Respectfully submitted,

S. Jack Hu
Vice President for Research

May 2019